Home
About Reistone
Company Profile
Management Team
R&D
Discovery
JAK Inhibitor
BTK Inhibitor
Clinical Development
JAK Inhibitor
Indications Under Development
Media
Press Release
In Media
Business Development
Business Development
Career
Job Opportunities
Contact Us
Home
关闭
返回
中文
Clinical Development
+ 查看更多
Home
>
Clinical Development
Discovery
JAK Inhibitor
BTK Inhibitor
Clinical Development
JAK Inhibitor
Indications Under Development
Menu
Menu
shut down
return
Discovery
return
JAK Inhibitor
BTK Inhibitor
Clinical Development
return
JAK Inhibitor
Indications Under Development
Clinical Development
JAK Inhibitor
SHR 0302 is an innovative JAK1 inhibitor with high selectivity. Reistone is currently carrying out global multi-center clinical programs of SHR 0302, in both oral and topical dosage forms..
